What is Emulate?
Established in 2013 and headquartered in Boston, Massachusetts, Emulate is commercializing Organs-on-Chips technology. This advanced human cell-based platform recreates organ-level function, enabling the modeling of organs in both healthy and diseased states. Emulate's technology offers a powerful alternative to traditional animal testing, providing more predictive and human-relevant data for pharmaceutical research, drug discovery, and personalized medicine. The company's commitment to scientific rigor and innovation positions it at the forefront of the biotechnology sector, driving advancements in understanding complex biological systems.
How much funding has Emulate raised?
Emulate has raised a total of $169M across 7 funding rounds:
Series A
$12M
Series B
$17M
Grant
$2M
Private Equity
$745K
Series C
$36M
Other Financing Round
$19.3M
Series E
$82M
Series A (2014): $12M with participation from NanoDimension and Cedars-Sinai
Series B (2016): $17M led by NanoDimension, ATEL Capital Group, ALS Finding a Cure, OS Fund, Laboratory Corporation of Americau00ae Holdings, and Cedars-Sinai
Grant (2017): $2M supported by National Center for Advancing Translational Sciences
Private Equity (2017): $745K, investors not publicly disclosed
Series C (2018): $36M backed by Starlight Ventures, ALS Investment Fund, SciFi VC, and Founders Fund
Other Financing Round (2020): $19.3M with participation from NanoDimension, Blue Ivy Ventures, ALSInvestment Fund, Northpond Ventures LLC, Cedars-Sinai, and Founders Fund LLC
Series E (2021): $82M led by Northpond Ventures and Perceptive Advisors
Key Investors in Emulate
NanoDimension
ND Capital is a venture capital firm established in 2002 that focuses on investing in disruptive technologies across life, physical, and data sciences. With $800M in assets under management, the firm operates in the United States and Europe, leveraging its teams in Silicon Valley, Switzerland, and the Cayman Islands to support portfolio companies in attracting capital and talent.
ATEL Capital Group
ATEL Capital Group is an international financial services company that for over 35 years has offered its clients a wide array of financial solutions including equipment leasing, asset-based lending, venture finance, lease administration and asset management.
ALS Finding a Cure
ALS Finding a Cure is funding research to treat and cure ALS through global research and nationwide advocacy. It develops technology and knowledge to accelerate diagnosis, thereby facilitating earlier treatment.
What's next for Emulate?
With its recent major strategic investment, Emulate is poised for accelerated growth and further development of its groundbreaking Organs-on-Chips platform. The substantial capital infusion is expected to fuel expansion into new therapeutic areas, enhance manufacturing capabilities, and broaden its market reach. Emulate's strategic focus on providing human-relevant data for drug development and disease modeling aligns with the increasing demand for more predictive and ethical research tools. The company's trajectory suggests a continued emphasis on scientific validation and strategic partnerships to solidify its leadership in the organoid and tissue engineering market.
See full Emulate company page
